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Abstract
One-third of monogenic inherited diseases result from premature
termination codons (PTCs). Readthrough of in-frame PTCs enables
synthesis of full-length functional proteins. However, extended
variability in the response to readthrough treatment is found
among patients, which correlates with the level of nonsense tran-
scripts. Here, we aimed to reveal cellular pathways affecting this
inter-patient variability. We show that activation of the unfolded
protein response (UPR) governs the response to readthrough treat-
ment by regulating the levels of transcripts carrying PTCs. Quanti-
tative proteomic analyses showed substantial differences in UPR
activation between patients carrying PTCs, correlating with their
response. We further found a significant inverse correlation
between the UPR and nonsense-mediated mRNA decay (NMD),
suggesting a feedback loop between these homeostatic pathways.
We uncovered and characterized the mechanism underlying this
NMD-UPR feedback loop, which augments both UPR activation and
NMD attenuation. Importantly, this feedback loop enhances the
response to readthrough treatment, highlighting its clinical impor-
tance. Altogether, our study demonstrates the importance of the
UPR and its regulatory network for genetic diseases caused by
PTCs and for cell homeostasis under normal conditions.
Keywords nonsense-mediated mRNA decay; premature termination codon;
readthrough treatment; unfolded protein response
Subject Categories Genetics, Gene Therapy & Genetic Disease
DOI 10.1002/emmm.201303347 | Received 4 August 2013 | Revised 3 March
2014 | Accepted 6 March 2014 | Published online 4 April 2014
EMBO Mol Med (2014) 6: 685–701
Introduction
About 30% of inherited and acquired diseases are attributable to
premature termination codon (PTC) through nonsense or frameshift
mutations (Mendell & Dietz, 2001; Kuzmiak & Maquat, 2006). In
recent years, an extensive effort has been made to develop therapeutic
approaches for in-frame PTCs aimed to promote translational
readthrough of the PTC and generate full-length functional proteins.
One such approach is readthrough by aminoglycoside antibiotics
(Burke & Mogg, 1985; Martin et al, 1989), synthetic aminoglycosides
(Rowe et al, 2011), and ataluren (PTC124) (Hirawat et al, 2007;
Welch et al, 2007; Kerem et al, 2008) that lead to translational read-
through of PTCs by the insertion of an amino acid at the stop codon
(Burke & Mogg, 1985; Martin et al, 1989; Van de Peer et al, 1994;
Fourmy et al, 1996; Recht et al, 1996, 1999; Fan-Minogue & Bedwell,
2007; Keeling et al, 2012). Hence, protein translation can continue
to the normal end of the transcript and a full-length protein is
generated. Many cancers are associated with PTCs. In terms of their
potential as anti-cancer agents, aminoglycosides have been shown to
interfere with the oncogenic process both in culture cells and in
mouse models (Bidou et al, 2012). Readthrough studies performed
in several colorectal cancer models demonstrated the restoration of
mutant APC, resulting in reduced oncogenic phenotypes both in vitro
and in vivo (Zilberberg et al, 2010; Floquet et al, 2011; Bordeira-
Carrico et al, 2012). Recently, several readthrough compounds have
been shown to enable repair of UV damage in xeroderma pigmento-
sum (XP) cells (Kuschal et al, 2013). These studies demonstrate the
therapeutic potential of readthrough for treating cancer.
Readthrough studies using aminoglycosides or ataluren,
performed in our center as well as in others, have revealed variable
responses to the treatment among cystic fibrosis (CF) patients carry-
ing PTCs (Wilschanski et al, 2000, 2003; Clancy et al, 2007; Kerem
et al, 2008; Sermet-Gaudelus et al, 2010). A variable response was
also observed among Duchenne muscular dystrophy (DMD) patients
carrying a PTC in the dystrophin gene and in a DMD mouse model
(Barton-Davis et al, 1999; Wagner et al, 2001; Dunant et al, 2003;
Politano et al, 2003). Readthrough efficiency is influenced by
several factors such as the PTC identity and the sequences
surrounding the PTC especially the fourth nucleotide immediately
after the stop codon (Linde & Kerem, 2008). Another important
factor is the level of transcripts available for readthrough. We have
previously found an extended variability among CF patients in the
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nonsense transcript level, which was correlated with their response.
A response was found only in patients with relatively high levels of
CFTR transcripts (Linde et al, 2007b; Kerem et al, 2008). Since the
transcripts serve as templates to the readthrough process, their level
is a limiting factor of the response. Different cellular mechanisms
can regulate the levels of transcripts carrying PTC. Our previous
results showed that the nonsense-mediated mRNA decay (NMD)
affects nonsense transcripts levels and modulates the response to
readthrough treatment (Linde et al, 2007b). NMD is a translation-
dependent surveillance mechanism conserved in all eukaryotic
organisms, from yeast to humans (Culbertson, 1999). The NMD
pathway detects and selectively degrades transcripts carrying PTCs,
thus preventing the accumulation of truncated proteins that might
be nonfunctional or deleterious due to dominant-negative or gain-
of-function effects (Losson & Lacroute, 1979; Frischmeyer & Dietz,
1999; Durand & Lykke-Andersen, 2011). The NMD degrades not only
aberrant transcripts from mutant genes, but is also an important
post-transcriptional regulatory mechanism degrading normal tran-
scripts from genes (encoding functional proteins) that harbor a
normal stop codon in a context that elicits NMD (Mendell et al,
2004; Chang et al, 2007; Neu-Yilik & Kulozik, 2008). The role of the
NMD mechanism in regulating gene expression and cell survival
highlights the important biological function of NMD as an RNA
surveillance mechanism under physiological conditions. Perturbation
of the NMD mechanism may have major implications as a result of
altered levels of many of its physiological substrates. Consistent with
this, aberrant conditions such as malignant transformation as well as
different cellular stress conditions involve NMD inhibition (Gardner,
2008, 2010; Wang et al, 2011a,b). Importantly, under conditions of
inefficient NMD, PTC-carrying transcripts tend to accumulate in the
cell enabling a better response to readthrough agents (Linde et al,
2007b). In addition, the translation of these transcripts is expected to
result in the accumulation of truncated proteins in the cell.
About one-third of all newly synthesized proteins in a cell are
secretory and transmembrane proteins. The transcripts of these
proteins are translocated into the endoplasmic reticulum (ER)
lumen, where they are translated. The resulting proteins are folded,
modified, and correctly assembled in the ER before being targeted to
the rest of the endomembrane system, cell membrane or secretion,
depending on their function and nature (Zhang & Kaufman, 2008).
When misfolded proteins accumulate in the ER, the UPR is induced
to restore cellular homeostasis by activating ER chaperones and
foldases and by inhibiting translation of new substrates. Accumula-
tion of unfolded proteins in the ER is the primary stress signal
sensed in metazoans by three parallel pathways, in each branch a
transmembrane protein: IRE1, PERK, or ATF6 senses the abnormal
condition in the ER lumen or membrane and transmits the signal to
the cytosol where a series of transcription factors carry information
to the nucleus (Walter & Ron, 2011). The UPR coordinates an adap-
tive response to the stress and alters the cellular transcriptional and
translational programs to enable cells to cope with the stressful
condition and to resolve the protein-folding defect (Kaufman, 1999;
Schroder, 2006; Brodsky, 2007; Zhang & Kaufman, 2008). Since
UPR activation attenuates the general translation in the cell, it was
recently shown to inhibit the NMD mechanism which is transla-
tional dependent (Wang et al, 2011b). However, this is expected to
perturb the cellular homeostasis under ER stress conditions and
increase the level of unfolded proteins.
In this study, we show that UPR activation regulates the levels of
transcripts carrying disease-causing PTCs, and by this governs the
response to readthrough treatment. Unbiased proteomic analyses
showed that there are substantial differences in UPR activation
between patients carrying PTCs that correlate with their response to
readthrough treatment. Furthermore, an inverse relationship
between the NMD and UPR processes was found in proteomic
analyses of primary cells from patients and in various cell lines,
suggesting a feedback loop between these two homeostatic mecha-
nisms. Importantly, NMD inhibition together with UPR activation
enhanced the response to readthrough treatment, highlighting the
functional role of the NMD-UPR feedback loop. We further revealed
and characterized a novel feedback loop between NMD and UPR
that augments both the activation of the UPR and the attenuation of
the NMD. Importantly, our study demonstrates that in order to
maintain cellular homeostasis under ER stress, UPR factors are
subjected to NMD, suggesting a novel, NMD-mediated mechanism
by which the cell attempts to enhance the UPR activity in response
to ER stress. Similarly, UPR itself attempts to activate the NMD by
increasing the level of NMD factors, despite the natural downregula-
tion caused by translation inhibition to resolve the ER protein load.
Altogether, our study demonstrates the importance of the UPR and
its regulatory network for genetic diseases caused by PTCs and for
cell homeostasis under normal conditions.
Results
Differential UPR activation between two patients carrying the
W1282X stop mutation in the CFTR gene
Aiming to reveal cellular pathways which play a role in the inter-
patient variability in the response to readthrough treatment, we
performed an unbiased analysis of the proteome of two CF patients
who are sisters, and whose parents are first-degree cousins, by high-
resolution quantitative mass spectrometry (Cox & Mann, 2011).
These sisters participated in a readthrough clinical trial (Wilschanski
et al, 2003). Although both are homozygous for the CFTR W1282X
allele, they differed in their response to the treatment, as measured
by the normalization of the nasal potential difference (NPD), and in
their CFTR transcript levels. Patient 6537 did not respond to the treat-
ment and had a lower level of CFTR transcripts than her sister,
patient 6538 (Wilschanski et al, 1995, 2000; Linde et al, 2007b). The
proteome analyses were performed on two EBV-transformed lympho-
blastoid cell lines derived from the two patients using the stable
isotope labeling in cell culture (SILAC) technique for accurate quanti-
fication (Mann, 2006). Out of the 6000 proteins identified, only 440
proteins showed a statistically significant different level between the
cell lines at a false discovery rate (FDR) of 0.05 (Fig 1). This very
high similarity likely reflects the similar genetic background of the
sisters as well as the precision of our proteomics quantification.
Interestingly, more than 10% of the proteins that significantly
changed (n = 43) are known ER resident proteins and can be acti-
vated by the UPR (Fig 1; examples are shown in Supplementary
Table S1). Unbiased enrichment analysis using the Fisher’s exact test
showed enrichment of a small number of gene ontology categories
and revealed a highly significant enrichment of ER proteins
(FDR < 0.02; Supplementary Table S2). Altogether, the proteomic
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results raise the possibility that the UPR has a role in the regulation
of readthrough treatment for patients carrying disease-causing PTCs.
UPR activation enables CFTR and XLF function following
readthrough treatment
To assess the effect of UPR activation on the response to read-
through treatment, we studied two genetic diseases caused by PTCs.
The first studied model system is CFP15a cells, a human epithelial
cell line derived from a nasal polyp of a CF patient carrying the
nonsense mutation W1282X and the splicing mutation 3849+10 kb
C->T (which also leads to a PTC) in the CFTR gene (Linde et al,
2007b). We treated these cells with G418 (an aminoglycoside antibi-
otic used for readthrough) together with UPR activation and exam-
ined the functional changes in the cells. As a functional output, we
examined the activity of the cAMP-activated chloride channel,
which is encoded by the CFTR gene. Untreated CFP15a cells showed
negligible chloride efflux (Fig 2, blue line). The readthrough agent
G418 or the UPR activator tunicamycin (TM) alone had a slight (but
not significant) increase in CFTR-mediated halide efflux (Fig 2, pink
and yellow lines); however, the combined treatment resulted in
considerable and significant improvement in halide efflux, implying
the presence of functional CFTR channels in these cells (Fig 2, light
blue line P-value = 0.016). Concomitant with these results,
combined treatment of UPR activation together with readthrough
treatment resulted in an increase in the level of CFTR proteins (Sup-
plementary Fig S6).
These results show that the response to readthrough treatment in
CFP15a cells was only possible following UPR activation.
Next we examined the effect of UPR activation following read-
through treatment in another disease model, a human fibroblast cell
line (P133) derived from a patient with immunodeficiency with
microcephaly, homozygous for the nonsense mutation R178X in the
Cernunnos/XRCC4-like factor (XLF) gene (Buck et al, 2006).
Cernunnos/XLF plays a role in the nonhomologous end joining
(NHEJ) DNA damage repair, as a part of a protein complex together
with DNA ligase IV and XRCC4 that ligate the two DNA ends. Fibro-
blasts from patients carrying Cernunnos/XLF mutations are radio-
sensitive and exhibit impaired DNA double-strand break (DSB)
repair following IR or radiomimetic drug treatment (Ahnesorg et al,
2006; Buck et al, 2006). To evaluate the effect of UPR on XLF func-
tion, we analyzed the phosphorylation of histone H2AX on Ser-139
(a measure for the amount of double-stand breaks) following DSB
induction with neocarzinostatin (NCS). Cernunnos/XLF mutated
cell line, P133, was treated for 10 min with NCS and allowed to
recover in regular media in the presence or absence of G418 and in
the presence or absence of UPR activation by dithiothreitol (DTT)
(Fig 3A). In P133 cells, the level of cH2AX (indicating the phosphor-
ylated form) increased following NCS treatment and stayed high for
15 h of recovery (Fig 3B), indicating an impaired repair of DSBs in
the absence of Cernunnos/XLF. G418 treatment by itself did not
reduce the level of cH2AX (Fig 3B and C); however, UPR activation
by DTT treatment together with readthrough by G418 resulted in
reduced levels of cH2AX (Fig 3A, lane 6 in comparison with lane 5
and Fig 3C), indicating that the XLF protein was functional in these
cells. These results indicate that UPR activation enables the
response to readthrough treatment in P133 cells. We further exam-
ined the effect of UPR activation following readthrough in these cells
by immunofluorescent analysis of cH2AX and 53BP1 colocalization,
for the quantification of the DNA double-strand break repair
(Supplementary Fig S1). Similar to the Western results, the immu-
nofluorescent analysis also shows that UPR activation by DTT
treatment together with readthrough by G418 significantly reduced
levels of DNA double-strand breaks.
Altogether, the results from both the CFTR and XLF disease
models indicate that indeed UPR activation plays an important role
in modulating the response to readthrough treatments of cells
carrying disease-causing PTC.
Log2(SILAC raƟo)
















Figure 1. Differential UPR activation between two patients carrying the W1282X stop mutation in the CFTR gene.
SILAC-based quantitative proteomic analysis of lymphoblastoid cell lines. A histogram of overall protein ratios shows high similarity between the patient-derived cells, with
only 440 showing statistically significant differences (Significance < 0.05; Significant). Significantly different ER resident proteins (ER) are higher in the responsive CF patient.
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UPR activation leads to upregulation of endogenous transcripts
carrying disease-causing PTCs
The level of the transcripts carrying PTCs is a limiting factor in
response to readthrough treatments, such that response is found
only in patients with relatively high levels of transcripts (Linde et al,
2007b; Kerem et al, 2008). We therefore examined the effect of UPR
activation on the level of transcripts carrying disease-causing PTCs.
To measure this effect, we analyzed cell lines derived from patients
carrying different disease-causing PTCs: the CFP15a carrying a PTC
in the CFTR gene (Linde et al, 2007b); P133, carrying PTC in
XRCC4-like factor (XLF) gene, as described above (Buck et al,
2006); and LPIN1, human primary fibroblasts derived from a patient
with myoglobinuria, homozygous to the nonsense mutation E215X
in the LPIN1 gene (Zeharia et al, 2008). UPR activation by DTT
treatment led to significant increases in the levels of CFTR, XLF1,
and LPIN1 transcripts (Fig 4A–C). These results highlight the dual
effect of UPR activation in regulating both transcripts and proteins
levels and shed a light on the mechanism by which UPR activation
regulates the response to readthrough treatment. It is important to
note that G418 had no effect on the level CFTR and XLF transcripts
(Supplementary Fig S2A), indicating that G418 by itself did not
contribute to the functional correction of the proteins.
We hypothesized that the effect of UPR on the transcript levels is
mediated through NMD regulation. In agreement with Wang et al
(2011b), we show that activation of UPR inhibits the NMD by show-
ing significant increases in the levels of known NMD substrates SC35
1.6 and SC35 1.7 (Sureau et al, 2001) (Fig 4, Supplementary Fig S3).
UPR activation by TM in CFP15a had the same effect on the transcript
levels of CFTR and known NMD substrates (Supplementary Fig S2B),
supporting the CFTR functional results presented in Fig 2.
The effect of NMD inhibition on the level of known NMD
substrates and transcripts carrying disease-causing PTCs was further
analyzed in CFP15a, P133, and LPIN1 cells. As can be seen in
Supplementary Fig S2C, the effect of NMD inhibition on the tran-
script levels was comparable to that observed following UPR activa-
tion (Fig 4). Hence, the UPR mechanism plays an important role in
modulating the response to readthrough treatments by allowing
transcripts carrying PTC to accumulate in the cell due to NMD atten-
uation. In order to verify that the upregulation of known NMD tran-
scripts as well as transcripts carrying disease-causing PTCs is
specific for NMD inhibition following UPR activation, and is not a
general effect on the cells, we have performed analysis of the tran-
script levels of a large number of genes. As can be seen in Supple-
mentary Fig S2D, DTT treatment did not lead to any change in their
level, indicating that the increased level of NMD substrates results
from NMD inhibition due to UPR activation and is not a general
effect of DTT treatment in the cells.
NMD inhibition activates the PERK-peIF2a UPR branch
The UPR and NMD mechanisms have an important role in modulat-
ing the response to readthrough treatment. Importantly, both mech-
anisms have a crucial role in maintaining homeostasis under
physiological and environmental conditions. Although it is no
wonder that translational attenuation causes a decrease in NMD, we
speculated that this decrease would cause the accumulation of NMD
physiologic transcripts and more truncated proteins. If these
proteins are transmembrane or secretory, then NMD inhibition
should, in return, lead to UPR activation. Based on Gene Ontology
(Ashburner et al, 2000), we created a list of approximately 6000




















































Figure 2. The effect of UPR activation on the CFTR chloride efflux following G418 treatment.
A Halide efflux was measured using the SPQ fluorescence assay. Forskolin (20 lM) and genistein (50 lM) were added (solid arrow) to stimulate CFTR-dependent ion
transport (rate of upward deflection tracks CFTR activity before and after pharmacologic stimulation). The findings indicate upregulation of CFTR following combined
treatment with G418 and tunicamycin. Dotted arrow = addition of dequenching buffer; double arrow = addition of quenching buffer.
B Summary data indicating stimulated efflux rate by treatment group. *P = 0.016 by ANOVA; n = 9–10 coverslips/condition, > 15 cells monitored per coverslip.
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(ER substrates). Using unbiased expression data, we identified ER
substrates which were upregulated following hUPF1 downregulation
in HeLa (Mendell et al, 2004) or HEK293T cells (our expression
arrays). Among the upregulated transcripts in HeLa cells (n = 244)
and HEK293 (n = 226), multiple transcripts (95 and 44, respec-
tively) corresponded to ER substrates, indicating that there is a large
number of transcripts processed in the ER that are regulated by the
NMD mechanism. These results strengthen the notion that indeed
under conditions of inefficient NMD, the UPR will be activated.
Recently, Sakaki et al (2012) showed that NMD inhibition indeed
leads to activation of the UPR through the IRE1a-spliced XBP1
branch (Supplementary Fig S4) as detected by a significant increase
in the level of spliced XBP1 transcripts similar to the increase found
following mild DTT-induced stress. Since NMD attenuation is
induced by the PERK-peIF2a UPR branch, we examined whether
NMD inhibition activates also this UPR branch. For this purpose, we
inhibited the NMD pathway using siRNA directed against one of its
essential factors, hUPF1 (Mendell et al, 2002). The analysis was
performed in two epithelial cell lines, HeLa and HEK293T, and in a
nasal epithelial cell line, CFP15a (Linde et al, 2007b). Western blot
analysis showed a significant sequence-specific downregulation of
UPF1, 48 h after transfection in HeLa cells and 72 h in HEK293 and
CFP15a cells (Fig 5A). Using RT-qPCR, we could show that UPF1
downregulation causes an increase in the levels of several known
physiological NMD substrates, SC351.6, SC351.7, and CARS (Sureau
et al, 2001; Mendell et al, 2004) (Fig 5B).
Next we investigated the effect of NMD inhibition on UPR activa-
tion by analyzing the phosphorylation of eIF2a (Shen et al, 2004;
Kohno, 2007). Using Western blot analysis, we detected a substan-
tial increase in the level of phosphorylated eIF2a in all three tested
cell lines (Fig 5A and Supplementary Fig S5) in a manner similar to
control cells treated with the known UPR activators, TM or DTT
(Fig 5C and Supplementary Fig S5) (Lemin et al, 2007). These
results indicate that NMD inhibition indeed leads to activation of
the PERK-peIF2a UPR branch. Activation of the PERK-peIF2a UPR
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Figure 3. The effect of UPR activation on XLF function following G418 treatment.
A, B P133 cells were grown in the presence or absence of 250 lg/ml G418 for 24 h with (A) or without (B) UPR induction by 10 mM DTT treatment for 3 h. Cells were
allowed to recover for 6 h and then treated with 0.65 pg/ll NCS for 10 min. Cells were then harvested at the indicated times following the NCS wash. Protein
extracts were prepared and analyzed by immunoblotting with anti-cH2AX and anti-tubulin antibodies.
C Quantification of cH2AX levels normalized to tubulin.
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crosstalk between these two regulatory pathways, implying a
mechanistic link between them.
A feedback loop between the NMD mechanism and the ER
stress response
We postulated that one way of creating a link between NMD and
UPR is by subjecting specific UPR factors to NMD regulation. We
therefore analyzed whether the transcript levels of key UPR factors
increase during NMD inhibition. For this, we inhibited the NMD
pathway using siRNA directed against UPF1 and analyzed the
expression levels of four known UPR factors: ASNS (Gjymishka et al,
2009), ATF3, ATF4, and CHOP (Fribley et al, 2011). We found that
NMD inhibition led to upregulation of all these transcripts (Fig 6A).
Thus, NMD modulates the expression levels of UPR factors.
A gene may be upregulated following UPF1 knockdown either
because it is a direct NMD target, or due to secondary effects. In
order to test whether our four genes are likely to be bona fide NMD
targets, we looked whether they harbor known NMD-triggering
features (Schweingruber et al, 2013): long 30 untranslated region
(30UTR), an intron more than 55 bases downstream of the stop
codon (deep intron), and an upstream open reading frame (uORF).
We have found that ASNS (ENST00000454046) harbors a deep
intron, ATF3 (ENST00000366987) has long 30UTR, and three
isoforms of ATF4 have uORFs (ENST00000337304, ENST000003-
96680, and ENST00000404241), whereas for the CHOP gene we
could not detect any of the known NMD-triggering classical features.
These results indicate that upregulation of ATF3, ATF4, and ASNS
transcripts (observed after UPF1 knockdown) is likely to result from
a direct NMD effect. This reveals a component of the NMD-UPR
feedback loop where, under ER stress conditions, NMD attenuation
increases the levels of these factors in an attempt to improve the
ability of the cells to resolve the ER protein load (Fig 7).
Downregulation of NMD upon UPR activation is expected to
increase ER load due to increased levels of misfolded proteins. While
activation of NMD is expected to alleviate ER stress, our results
clearly show that UPR activation inhibits rather than activates NMD.
Recently, it has been shown that the efficiency of NMD is tightly
regulated by a negative feedback in which low NMD activity induces
an increase in the transcript levels of NMD factors (Chan et al, 2007;
Yepiskoposyan et al, 2011). This prompted us to investigate whether





































































































Figure 4. UPR activation leads to upregulation of transcripts carrying disease-causing PTCs.
A–C CFP15a (A), LPIN1 (B), and P133 (C) cells were treated with DTT (10 mM) for 2, 3, and 5 h. The level of SC35 1.6, SC35 1.7 and the level of CFTR or LPIN1 or XLF1
transcripts were measured by RT-qPCR. The values shown are the average fold change (mean  s.e.m.) from at least three independent experiments relative to
nontreated cells. Values were normalized against transcripts of RNA polymerase II gene. Statistical analysis was performed using Student’s t-test (one-tailed,
paired). *P < 0.05, **P < 0.01, ***P < 0.001.
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and upregulate the mRNAs of NMD factors. Indeed, ER stress
induced by DTT significantly increased the mRNA levels of the NMD
autoregulated factors UPF2, UPF3a, UPF3b, SMG1, SMG5, SMG6,
and SMG7 (Fig 6B). This increase was similar to that observed
following direct NMD inhibition by siRNA directed against hUPF1
(Fig 6B). Two of the NMD factors, hUPF3a and SMG7, were upregu-
lated following UPR activation but not under hUPF1 downregulation
(Fig 6B), suggesting that the UPR has a broader effect on the NMD
autoregulated factors. Overall, our results show an inverse relation-
ship between NMD factors transcript levels and the NMD activity.
Moreover, these results demonstrate that cells have evolved mecha-
nisms, which attempt to increase NMD function under conditions of
folding stress, despite a global reduction in translation.
We have shown that UPR activation inhibits NMD and that NMD
inhibition activates UPR, thereby suggesting that there may be a
feedback loop between these two cellular homeostatic mechanisms.
To investigate this, we tested whether NMD inhibition augments the
response to induction of ER stress. We first analyzed the levels of
phospho-eIF2a and spliced XBP1 in HEK293T cells treated with DTT
with or without hUPF1 downregulation. Both phospho-eIF2a and
spliced XBP1 increased significantly in the combined treatment in
comparison with DTT treatment or hUPF1 downregulation alone
(Fig 6C and D, Supplementary Fig S4). Next we analyzed the
combined effect of NMD inhibition and UPR activation on the levels
of physiological substrates of NMD. In agreement with the previous






















































































Figure 5. NMD inhibition activates the PERK-peIF2a UPR branch.
A, B HEK293T, HeLa, and CF15a cells were transfected with siRNA against hUPF1 or nonspecific control siRNA (scr) for 48 or 72 h. (A) Protein extracts were prepared
and analyzed by immunoblotting with anti-hUPF1, anti-tubulin, and anti-peIF2a antibodies. (B) Levels of SC35 1.6, SC35 1.7, and CARS transcripts were measured
by RT-qPCR. The values shown are the average fold change (mean  s.e.m.) from at least three independent experiments relative to nontreated cells or cells
transfected with a nonspecific control siRNA. Values were normalized against transcripts of RNA polymerase II gene (HEK293T and HeLa) or GAPDH (CFP15a). The
values shown are the average fold change (mean  s.e.m.) from at least three independent experiments relative to nontreated cells. Values were normalized
against transcripts of RNA polymerase II gene. Statistical analysis was performed using Student’s t-test (one-tailed, paired). *P < 0.05, **P < 0.01, ***P < 0.001.
C HEK293T, HeLa, and CFP15a cells were treated with TM (25 lg/ml) for 3 h or DTT (10 mM) for 2 h. Protein extracts were prepared and analyzed by
immunoblotting with anti-tubulin and anti-peIF2a antibodies.
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combined treatment as would be expected from synergistically
acting pathways (Fig 6E). These results strongly support the exis-
tence of a feedback loop between the two homeostatic mechanisms,
NMD and UPR (Fig 7).
To further test the NMD-UPR feedback loop, we interfered with
the UPR-mediated NMD inhibition. For this, we downregulated
PERK expression and analyzed the effect of DTT treatment on the
IRE1-spliced XBP1 UPR branch. PERK phosphorylates eIF2a to
attenuate translation initiation and thus is responsible for the NMD
attenuation. As a control, we confirmed that PERK downregulation
results in reduced eIF2a phosphorylation and NMD inhibition as
previously described (Wang et al, 2011b) (Fig 6F). Most impor-
tantly, PERK downregulation reduced NMD inhibition in response
to DTT treatment (Fig 6G). Interestingly, in these same cells, UPR
activation, through the IRE1 branch, was also reduced despite the
fact that one might expect compensation during the loss of one
signaling arm (Fig 6H). These results suggest that proper function of
NMD reduces the ER stress further supporting the feedback loop
between NMD and UPR mechanisms (Fig 7).
Finally, we analyzed the NMD-UPR feedback loop in our lympho-
blastoid cell lines derived from the two sisters (Fig 1). For this, we
have analyzed the transcript level of spliced-XBP1 and found an
higher level of this UPR factor in the cell line derived from the
responding sister (patient 6538) compared to the level in the nonre-
sponding sister (patient 6537) (Fig 6I). This result fully supports the
differences found in the proteomic analyses between these cell lines
(Fig 1). We further identified higher transcript levels of known
NMD substrates (SC35 1.6, SC35 1.7, and SMG1) in the cells from
the responding sister (Fig 6I). Altogether, the analyses in the patient
cell lines support the feedback-loop model.
A negative correlation between NMD and UPR factors in vivo
The feedback loop described above is suggested as a general cellu-
lar homeostatic mechanism. To examine its generality, we first
expanded our SILAC analysis to 16 samples of lymphocytes
isolated from blood samples of CF patients, all carrying a stop
mutation in the CFTR gene. The patients are currently participat-
ing in a phase IIb clinical trial using the readthrough drug ataluren
(PTC124), which is expected to be completed in 2014. We exam-
ined the levels of the core NMD factors as well as ER resident
proteins that are activated under conditions of UPR activation
whose level differed between the CF sisters (Fig 1 and Supplemen-
tary Table S3). The results show a statistically significant negative
correlation between the levels of NMD and UPR factors
(Spearman’s rank correlation = 0.97) (Fig 8B). As can be seen in
Fig 8, in patients that have high levels of NMD factors, the levels
of UPR factors are low and vice versa (Fig 8). These results
highlight the inverse relationship between the two processes both
in vitro (Fig 7) and in vivo.
We hypothesized that this relationship is not limited to disease-
related cells harboring PTC mutations, but is rather a more general
regulatory mechanisms of gene expression. We therefore performed
a similar analysis on a recently published large-scale proteomic
dataset of eleven commonly used cell lines K562, RKO Jurkat,
HEK293, LnCap, MCF7, U2Os, HepG2, GAGM, and A549 (Geiger
et al, 2012). In agreement with the CF samples, a perfect negative
correlation between the levels of NMD and UPR factors was found
(Fig 8C and D; Spearman’s rank correlation = 1). Altogether, the
proteomic results show a clear negative correlation between NMD
and UPR, indicating that there is a mechanistic link between them.
This feedback loop has a role under physiological conditions and in
human genetic diseases resulting from PTCs.
NMD inhibition together with UPR activation enhances the
response to readthrough treatment
The NMD-UPR feedback-loop mechanism predicts that NMD inhibi-
tion together with UPR activation enhances the response to read-
through treatment, in cells carrying disease-causing PTCs, compared
to the effect of each treatment alone (NMD inhibition or UPR activa-
tion). To evaluate the effect of UPR activation together with NMD
inhibition on XLF function following readthrough, we analyzed the
ability of P133 cells (carrying a PTC in the XLF gene) to repair DNA
DSBs, reflecting the XLF function, by analyzing the levels of ubiqui-
tylated cH2AX (UB-cH2AX). Ubiquitylation of cH2AX is an impor-
tant event in DNA damage response (Messick & Greenberg, 2009;
Sharma et al, 2014) that facilitates the recruitment of DDR factors
and might affect chromatin structure, leading to repair of the
damage (Bergink & Jentsch, 2009; Messick & Greenberg, 2009).
P133 cells transfected with siRNA directed against hUPF1 (for NMD
inhibition) or scrambled control were treated for 10 min with NCS
and allowed to recover in a regular media in the presence or
absence of G418 and in the presence or absence of UPR activation
by DTT. We have analyzed the repair efficiency of DSBs in UPF1 KD
cells compared to control cells for each treatment (Fig 9A). The
levels of Ub-cH2AX increased following NCS treatment and stayed
high for 15 h of recovery (lanes 2 and 3, 7, and 8). G418 treatment
by itself did not repair the DSBs (compare lane 4 to lane 3). Since
UPF1 KD caused DSBs (compare lane 6 to lane 1), the level of
Ub-cH2AX in all KD samples was normalized according to nontreat-
ed UPF1 KD. UPF1 KD together with readthrough by G418 resulted
in DSBs repair. Importantly, the most efficient repair by readthrough
was observed following both activation of UPR and NMD inhibition
(Fig 9B). These results show an improved restoration of the XLF
function following readthrough under combined NMD and UPR
treatments and highlight the functional role of the NMD-UPR feed-
back loop in modulating readthrough treatment.
Discussion
Here, we show that UPR governs the response to readthrough treat-
ment (Figs 1–4). Proteome analyses show a significant negative
correlation between the UPR and NMD (Fig 8), suggesting a feed-
back loop between these two homeostatic mechanisms. Importantly,
combined NMD inhibition and UPR activation enhanced the
response to readthrough treatment (Fig 9), shedding a new light on
the functional role of the NMD-UPR feedback loop. We further
uncovered and characterized this novel negative feedback loop,
which augments both the activation of the UPR and the inhibition of
the NMD. Altogether, these results highlight the importance of the
NMD and UPR mechanisms to maintain homeostasis under normal
conditions and in genetic diseases caused by PTCs.
Variability in NMD efficiency is found in cell lines, tissues, and
among individuals, suggesting that the efficiency of NMD is an
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inherent feature of cells (Holbrook et al, 2004; Linde et al, 2007a)
that can be modulated by genetic traits (sequence variations)
(Tarpey et al, 2007), environmental conditions (hypoxia, amino
acid starvation, etc.) (Wang et al, 2011b), or aberrant cellular
regulation (tumorigenicity) (Wang et al, 2011a). Our results show-
ing a feedback loop between NMD and the UPR suggest that either
the variability in UPR activation results from variability in NMD
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Both NMD and UPR factors are regulated by post-translational
modifications, including phosphorylation (Chang et al, 2007; Ron &
Walter, 2007; Popp & Maquat, 2013). In the future, analysis of post-
translational modifications will add another layer of information
about the regulation of these processes.
About one-third of all monogenic inherited diseases result from
PTCs, which are subjected to NMD (Kuzmiak & Maquat, 2006). One
of the approaches for the treatment of patients carrying PTCs is
readthrough by drugs affecting the ribosome decoding site, such as
aminoglycoside antibiotics (Linde & Kerem, 2008) and more recently
ataluren (PTC124) (Kerem et al, 2008; Sermet-Gaudelus et al, 2010).
Readthrough studies often reveal unexplained variable responses to
the treatment (Barton-Davis et al, 1999; Wilschanski et al, 2000,
2003; Wagner et al, 2001; Dunant et al, 2003; Politano et al, 2003;
Clancy et al, 2007; Kerem et al, 2008). Our results show the impor-
tance of UPR in regulating the response to readthrough treatment in
CF patients (Fig 1, patient 6538 relative to patient 6537). We have
previously shown that the level of nonsense transcripts is a limiting
factor in the response to readthrough treatments (Linde et al, 2007b;
Kerem et al, 2008). Here, we found that the expression level of tran-
scripts carrying disease-causing PTCs can be modulated by UPR acti-
vation (Fig 4), supporting our basic finding that activation of the
UPR leads to downregulation of NMD activity (Fig 4 and Supplemen-
tary Fig S3) and shedding light on the cellular mechanism by which
UPR activation governs the response to readthrough treatment
(Figs 2 and 3). UPR induction results in translation attenuation lead-
ing to NMD inhibition; therefore, UPR induction provides a mecha-
nism by which transcripts carrying PTC can be rescued and serve as
a template for readthrough treatment. It is important to note that in
the two disease models: CFTR and XLF, G418 alone did not have a
significant effect on the protein function, indicating that upregulating
the level of the PTC-bearing transcripts is required for a successful
readthrough treatment. These results prove that UPR is a modifier of
the response to readthrough treatment and therefore show for the
first time that UPR plays a role in modulating the response to a muta-
tion-specific treatment. It is interesting to note that several studies
have shown upregulation of transcripts carrying PTCs following
readthrough treatments using suppressor tRNA (Sako et al, 2006),
G418 (Correa-Cerro et al, 2005), or amlexanox (Gonzalez-Hilarion
et al, 2012) in mammalian cells. In these cases, the readthrough
agents also inhibit the degradation of transcripts carrying PTCs.
Many human diseases are associated with ER stress and UPR
activation (Zhang & Kaufman, 2008; Austin, 2009). For example,
UPR is triggered by infection and inflammation in CF airway epithe-
lial cells due to intensive synthesis of inflammatory mediators and
defensive factors which results in an increased flux of these newly
synthesized proteins into the ER (Bartoszewski et al, 2008; Martino
et al, 2009; Ribeiro & Boucher, 2010). Interestingly, cancer progres-
sion is identified with rapidly proliferating cells which require
























Feedback-loop regulatory network between the NMD and UPR pathways
augments both the activation of the UPR and the attenuation of NMD and
confers homeostasis under genetic, environmental, and/or cellular insults.
Figure 6. A positive feedback loop between the NMD and the UPR mechanisms.
A HEK293T cells were transfected with siRNA against hUPF1 or nonspecific control siRNA (scr) for 72 h. Levels of ATF3, ATF4, CHOP, and ASNS transcripts were
measured by RT-qPCR. The values shown are the average fold change (mean  s.e.m.) from at least three independent experiments relative to nontreated cells.
Values were normalized against transcripts of RNA polymerase II gene. Statistical analysis was performed using Student’s t-test (one-tailed, paired). *P < 0.05,
**P < 0.01, ***P < 0.001.
B HeLa cells were treated with DTT (10 mM) for 2 and 5 h or transfected with siRNA against hUPF1 or nonspecific control siRNA (scr) for 48 h. The levels of the NMD
factors transcripts were measured by RT-qPCR. Data were quantified and statistically analyzed as in (A).
C–E HEK293T cells were transfected with siRNA against hUPF1 or nonspecific control siRNA (scr) for 72 h with or without DTT treatment (10 mM) for 2 or 3 h. (C)
Protein extracts were prepared and analyzed by immunoblotting with anti-hUPF1, anti-tubulin, and anti-peIF2a antibodies. (D) Levels of spliced XBP1 and (E) SC35
1.6, CARS, SMG1, and ATF3 transcripts were measured by RT-qPCR. Data were quantified and statistically analyzed as in (A). All the changes following UPR
activation by DTT and UPF1 downregulation were significantly higher compared to nontreated or scr cells. Black asterisks: scr DTT/siUPF1 DTT. Gray asterisks:
siUPF1 DTT/siUPF1.
F–H HEK293T cells were transfected with siRNAs against PERK or nonspecific control siRNA (scr) for 72 h with or without DTT treatment (10 mM) for 3 h. (F) Protein
extracts were prepared and analyzed by immunoblotting with anti-PERK, anti-tubulin, anti-b catenin, and anti-peIF2a antibodies. (G) Levels of SC35 1.6, CARS, and
SMG1. (H) Levels of spliced XBP1 (P-value = 0.05).
I SC35 1.6, SC35 1.7, SMG1 and sXBP1 transcripts were measured by RT-qPCR. Data represent the ratio between 6538 and 6537 lymphoblastoid cell lines. Data were
quantified and statistically analyzed as in (A).
◂
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Figure 8. A negative correlation between NMD and UPR factors.
A–D Hierarchical clustering (A, C) and scatter plots (B, D) of 58 NMD and UPR factors in 16 primary lymphocytes from CF patients (A, B) and commonly used cell lines
(Geiger et al, 2012) (C, D). For the scatter plots, we averaged the normalized ratio values (primary lymphocytes) or normalized intensities (cell lines) of each group
of proteins (NMD or UPR).
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2013), resulting in activation of the UPR. In the context of read-
through therapy, an inefficient NMD, as an inherited character of
the cell or as a result of UPR activation, is expected to lead to upreg-
ulation of nonsense transcripts and by that to improve the response
to the treatment. Strategies designed to induce the UPR locally may
therefore improve the therapeutic benefits afforded by readthrough
therapy. Moreover, we envision that in the future, screens for
patients with high UPR activation will identify patients with higher
potential to respond to readthrough treatment.
It is interesting to note that UPR activation by itself might have
the potential to improve the CFTR function of the truncated
W1282X protein. As seen in Fig 2, there is a slight (although not
significant) increase in CFTR function following TM treatment
alone. Recently, it has been shown that CFTR proteins truncated
early in the nucleotide binding domain 2 (up to aa 1248) are
exported from the ER, escape the ER quality control, and form a
stable and functional chloride channel that is stable at the cell
surface (Cui et al, 2007). Furthermore, HeLa cells stably express-
ing the W1282X CFTR cDNA show partial restoration of the CFTR
function by enhanced expression of CFTR proteins carrying this
nonsense mutations (Rowe et al, 2007). Therefore, imbalance
between the protein load in the ER (as a result of overload
induced by cDNA expression or as a result of impaired protein
folding due to TM treatment) and the capacity of the ER enables
the escape of truncated misfolded protein from the ER quality
control. In cases in which the truncated protein has residual activ-
ity, as in case of the truncated W1282X CFTR protein, this will
lead to a better CFTR function. These results suggest that patients
harboring the W1282X mutation are susceptible to CFTR rescue by
enhanced expression and localization of the CFTR truncated
proteins when sufficient levels are localized to the plasma
membrane due to UPR induction. Hence, UPR induction may be a
viable way to provide therapeutic benefit for some diseases, either
by increasing the level of partially functional truncated proteins or
in combination with readthrough therapy to restore full-length
functional proteins. We propose that in disorders like CF, where
as little as 10–15% of normal channel function is sufficient for
clinical rescue of the disease phenotype (Chu et al, 1992), mild
UPR induction together with readthrough treatment can serve as a
novel therapeutic approach.
The proteomic results clearly show a negative correlation
between NMD and UPR factors among patients and cell lines. The
entire proteomic results reflect the novel feedback loop between
the NMD and UPR characterized in this study (Fig 7). We have
further shed light on the mechanism activating the UPR by discov-
ering that NMD inhibition modulates the transcription levels of a
substantial number of ER substrates. This suggests that NMD
normally has a role in regulating the protein load in the ER as part
of the cellular homeostasis. Furthermore, we find that PERK-peIF2a
is a driving force of the NMD-UPR feedback loop (Figs 5 and 6G).
Another mechanistic aspect of the NMD-UPR feedback loop
emerging from our data is that UPR factors are subjected to NMD
(Fig 6A). This suggests a novel, NMD-mediated mechanism by
which the cell attempts to enhance the UPR activity in response to
ER stress. Similarly, UPR can rescue the inherent propensity of





























































Fold change in Ub-γH2AX 
Figure 9. NMD inhibition together with UPR activation enhances the response to readthrough treatment.
P133 cells were transfected with siRNA against hUPF1 or nonspecific control siRNA (scr) for 72 h. DTT, G418, and NCS treatments were performed as described in Fig 3A.
A Protein extracts were prepared and analyzed by immunoblotting with anti-hUPF1, anti-cH2AX, and anti-tubulin antibodies.
B Quantification of Ub-cH2AX levels normalized to tubulin. All siUPF1 samples were normalized according to the nontreated siUPF1. Data represent the fold change of
Ub-cH2AX in siUPF1 compared to scr, for each indicated treatment. Quantification is an average of two experiments.
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fied NMD homeostasis loop (Chan et al, 2007; Yepiskoposyan et al,
2011). Under conditions of general translation attenuation, NMD
inhibition results in upregulation of NMD factors transcripts, in an
attempt to improve NMD function (Fig 6B). The feedback loop
between NMD and UPR implies that the differential sensitivity of
cells to activate the UPR may also be the basis of variability in NMD
efficiency. Similarly, variability in NMD efficiency may result from
variable sensitivity to UPR activation.
Importantly, NMD inhibition together with UPR activation
enhanced the response to readthrough treatment (Fig 9) highlight-
ing the functional role of the NMD-UPR feedback loop in therapeutic
approaches aimed to promote translational readthrough.
Altogether, our study provides new insights into the cellular
mechanisms and the interplay between them in regulating read-
through and may enable the development of novel drugs aimed to
improve the response to readthrough therapies for many human
genetic diseases caused by PTCs.
Materials and Methods
Cell culture and treatments
HeLa and HEK239T cells were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum (FCS).
CFP15b cells described previously (Linde et al, 2007b) were grown
in bronchial epithelial cell basal medium. LPIN1 primary fibroblasts
were grown in Dulbecco’s modified Eagle’s medium supplemented
with 15% fetal calf serum (FCS). P133 cells described previously
(Buck et al, 2006) were grown in RPMI medium supplemented with
10% fetal calf serum. 6537 and 6538 cell lines are EBV-immortal-
ized B cells derived from CF patients and these cell lines were
grown in RPMI medium supplemented with 15% fetal calf serum.
UPR induction was performed using 10 mM dithiothreitol (DTT)
or 25 lg/ml tunicamycin (TM) for the indicated times.
RNA interference
Short-interfering RNA (siRNA) directed against UPF1 (Dharmacon)
were described by Mendell et al, (2002). Three siRNA sequences
directed against PERK (Invitrogen) were used: 50-GGCAGUGGA-
GUUUCUUCACAGUAAA-30, 50-CACCAGUAGCAA AUCUUCUUCU-
GAA-30, and 50-CAGAUGGAGAGAGUCAGGACCUUAA-30.
Nonspecific control oligo (IDT) was used as control siRNA.
Oligofectamine (Invitrogen) was used for transfection. Cells were
harvested 48 h in HeLa cells, 72 h in HEK293T or CFP15a cells and
96 h in LPIN1 cells after transfection.
RNA analysis
Total RNA was extracted using the RNeasy extraction kit (QIAGEN).
RNA-less and reverse transcriptase-less reactions were used as
controls. Complementary DNA (cDNA) synthesis was performed
using the High Capacity cDNA Reverse Transcription kit (Applied
Biosystems). Real-time PCR was subsequently performed in ABI
7500 using a Power SYBR green PCR master Mix (Applied Biosys-
tems).The expression level was normalized to the transcript levels
of RNA polymerase II gene and GAPDH. Specific primers for these
PCRs were designed using the Primer Express software. For statisti-
cal analysis, Student’s t-test was used. The actual P-values are
summarized in Supplementary Table S5. The sequences of all used
primers are described in Supplementary Table S4.
Western blot analysis
10% and 6% polyacrylamide gels were used for protein separation.
The gel was transferred to a nitrocellulose membrane, and antibody
hybridization and chemiluminescence were performed according to
the standard procedures. The primary antibodies used in this analy-
sis were rabbit anti-hUPF1, kindly provided by Andreas E. Kulozik
(University of Heidelberg, Heidelberg, Germany), rabbit anti-
phosphor-eIF2a (Cell Signaling), rabbit anti-PERK (Cell Signaling),
mouse anti-CFTR (596) kindly provided by John R Riordan, mouse
anti-tubulin (SIGMA) and mouse anti-b-catenin (BD Transduction
Laboratories). HRP-conjugated anti-rabbit and anti-mouse second-
ary antibodies were obtained from Jackson ImmunoResearch
Laboratories.
Immunofluorescence
P133 cells were fixed in 3.7% formaldehyde/PBS for 10 min,
permeabilized with 0.5% Triton/PBS, and blocked with 10% FCS/
PBS. The primary antibodies used were mouse anti-cH2AX (Upstate
Biotechnology) and rabbit anti-53BP1 (Bethyl Laboratories). Appro-
priate Cy3- and Cy5-conjugated secondary antibodies were added
(Jackson ImmunoResearch Laboratories). Images were taken with a
Bio-Rad confocal microscope, and analysis was performed using
ImageJ. Colocalization of both signals was considered as a DSB foci.
Foci analysis was performed from at least 45 nuclei for each
condition.
Microarray data analysis
RNA was extracted from HEK293T cells transfected with siRNA
directed against UPF1 or nonspecific control oligo (scr), using the
RNeasy extraction kit (QIAGEN). Hybridization to GeneChip Human
Gene 1.0 ST expression arrays, washing and scanning were
performed according to the manufacturer’s protocol (Affymetrix).
Arrays were analyzed using RMA probeset condensation algorithm
(Expression Console, Affymetrix). Genes were considered differen-
tially expressed when the average change was over 1.5-folds.
Analysis of published datasets of gene expression following hUPF1
downregulation in HeLa (GSM29530, GSM29531, GSM29532, and
GSM29534) was performed as described previously (Mendell et al,
2004). ER substrates list was based on the dataset of The Gene
Ontology Consortium (Ashburner et al, 2000) using: GO:0005886,
GO:0005887, GO:0031226, GO:0005615, GO:0005578, GO:0044420,
GO:0005794, GO:0030130, GO:0005768, and GO:0005764. We
exclude genes which appear at: GO:0030130, GO:0010787,
GO:0010788, GO:0010009, GO:0032419.
SILAC labeling and sample preparation for MS analysis
6537 or 6538 cells were SILAC-labeled by culturing them for 14
doublings in medium deprived of lysine and arginine and supple-
mented with heavy forms of these amino acids: 13C6
15N4-arginine
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(Arg-10) and 13C6
15N2-lysine (Lys-8) or with the light amino acids.
Medium was supplemented with dialyzed serum to eliminate the
light amino acids from the serum. Cells were harvested in lysis
buffer consisting of 4% SDS, 100 mM Tris–HCl, pH 7.6, and
100 mM dithiothreitol (DTT). Lysates were incubated for 10 min at
95°C and then briefly sonicated.
For the comparison between 6537 and 6538 cells, we performed
five biological replicates including label swap of heavy and light
labeled cells, to eliminate potential effects of the labeling. In each
replicate, equal protein amounts of heavy and light lysates were
combined and the rest of the experimental procedure was performed
for the combined lysate. For two replicates, lysates were separated
by 6–12% gradient gel followed by gel staining with colloidal blue
staining (Invitrogen). Each gel lane was cut into 10 fractions and
proteins were trypsin-digested according to the in-gel digestion
protocol [ref: PMID 17406544]. Three replicates were trypsin-
digested in solution and peptides were separated using the off-gel
fractionator [PMID:19003865]. In the analysis of patient samples,
equal protein amounts of the nonlabeled lysates from the primary
cells were combined heavy labeled lysate of 6537 cells that served
as an internal standard for quantification [PMID: 21293456]. Lysates
were digested using the FASP protocol [PMID: 19377485] followed
by peptide separation into six fractions by strong anion exchange in
a stageTip format [PMID: 19848406]. After each of the protocols,
peptides were purified on C18 StageTips [PMID: 12585499] prior to
MS analysis.
LC-MS analysis
LC-MS analyses of the cell lines were performed on an Easy-nano-
LC coupled to an LTQ Orbitrap XL mass spectrometer (Thermo
Fisher Scientific). Peptides were separated on a C18 column (15 and
75 lm i.d. and 3 lm Reprosil resin), using a 100-min gradient of
water/acetonitrile. Patient samples were analyzed on an EASY-nLC-
1000 coupled to the Q-Exactive mass spectrometer (Thermo Fisher
Scientific). Peptides were separated on a 50-cm C18 column (Dionex)
using a 200-min gradient of water/acetonitrile.
Data analysis
Raw MS data analysis was done in the MaxQuant environment
[PMID: 19029910] ensuring 0.01 false discovery rate (FDR) on the
peptide and protein levels.
For the analysis of NMD and UPR proteins in the patient samples
and the deep proteomes of cell lines, we extracted the quantitative
data of 71 selected proteins [NMD core proteins and UPR proteins
which showed significantly different levels between 6537 and 6538
cell lines (Supplementary Table S3)]. Hierarchical clustering of
proteins was performed on logarithmized ratios for the patient
samples and logarithmized intensities for the cell line proteomes
using Euclidean distances between averages. Prior to clustering,
quantitative values were z-score-normalized on the protein and
sample axes. Spearman’s correlation between UPR and NMD
proteins was determined on normalized values after averaging each
group of proteins for each sample. Enrichment analysis was
performed using Fisher’s exact test with an FDR value of 0.02.
Statistical analysis was done with the Perseus program in the
MaxQuant environment [PMID: 21548781].
Halide efflux assay (SPQ)
Cells were seeded onto Vectabond-treated glass coverslips and grown
to approximately 80% confluence. Immediately prior to study, cells
were hypotonically loaded with halide-quenched dye (6-methoxy-N-
(3-sulfopropyl) quinolinium, SPQ, 10 mM, Molecular Probes Inc.,
Eugene, OR) for 10 min and then placed in a quenching NaI-based
buffer (King & Sorscher, 2000). CFTR robustly conducts iodide in
addition to chloride, HCO3 , and other anions, allowing use of iodide
quench as a measure of macroscopic channel activity. Cells were
mounted in a specially designed perfusion chamber, and fluores-
cence was monitored using an inverted Nikon Diaphot microscope
(Tokyo, Japan; excitation at 350 nm, emission at > 410 nm), an Easy
Ratio Pro imaging system (PTI, Birmingham, NJ), and a CoolSNAP
HQ2 camera (Photometrics, Tucson, AZ). Baseline fluorescence was
initially studied in NaI buffer (above) followed by dequenching
NaNO3 solution (King & Sorscher, 2000). CFTR agonists (20 lM fors-
kolin, 50 lM genistein) were added to activate channel gating, after
which NaI buffer was again perfused. Fluorescence was normalized
for each cell versus baseline and increases shown as percent above
basal (quenched) values. For each coverslip, > 15 individual cells
were monitored. Average stimulated change in fluorescence from
each coverslip was used for statistical analysis (n = 9–10 coverslips
per condition; data recorded on five separate days). Data were
expressed as mean  s.e. and tested for significance using ANOVA.
Results with P < 0.05 were considered significant.
The paper explained
Problem
One-third of inherited diseases, caused by a defect in one gene, result
from stop mutations (also defined as premature termination codons,
PTCs). In recent years, an extensive effort has been made to develop
therapeutic approaches for PTCs aimed to promote translational read-
through of the PTC and generate full-length functional proteins.
Several readthrough approaches have been developed, including the
use of aminoglycosides or ataluren. However, extended variability in
the response to readthrough treatment is found among patients. Here,
we aimed to reveal cellular pathways affecting this inter-patient vari-
ability.
Results
We show that activation of the unfolded protein response (UPR), a
homeostatic mechanism aimed to resolve protein-folding defects in
the ER, governs the response to readthrough treatment by regulating
the levels of transcripts carrying PTCs. Proteomic analyses showed
substantial differences in UPR activation between patients carrying
PTCs, correlating with their response. We further found a significant
inverse correlation between the UPR and another homeostatic mecha-
nism, the nonsense-mediated mRNA decay (NMD), suggesting a feed-
back loop between these pathways. We uncovered and characterized
the mechanism underlying this NMD-UPR feedback loop. Importantly,
this feedback loop enhances the response to readthrough treatment.
Impact
These results provide new insights into the cellular mechanisms and
the interplay between them in regulating readthrough and may
enable the development of novel drugs aimed to improve the
response to readthrough therapies for many human genetic diseases
caused by PTCs.
EMBO Molecular Medicine Vol 6 | No 5 | 2014 ª 2014 The Authors
EMBO Molecular Medicine UPR modulates readthrough treatment Yifat S Oren et al
698
Since the SPQ assay is not well suited for multiple, timed drug
additions, especially when some of the treatments (such as DTT)
are borderline toxic and have their own potential for interrupting
distinct targets in various pathways, we used TM in this set of
experiments, which was less toxic to the cells.
Sequence analysis of known NMD-triggering features
Deep intron is defined as any intron located more than 55 nucleo-
tides downstream of a stop codon. A 30UTR is considered long if its
length is at least 1000 nt. uORF is an ORF upstream of the primary
ORF (i.e., in the 50UTR) that has an optimal Kozak signal (GCC[A/
G]CCaugG[not U]). We tested all isoforms of ASNS, ATF3, ATF4,
and CHOP taken from Ensembl (Flicek et al, 2013).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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